Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis

Trial Profile

Phase 3, Multicenter, Randomized Study Comparing CNTO 1275 and Etanercept for the Treatment of Moderate to Severe Plaque Psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Ustekinumab (Primary) ; Etanercept
  • Indications Plaque psoriasis
  • Focus Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms ACCEPT
  • Sponsors Centocor
  • Most Recent Events

    • 16 Jun 2018 Results evaluating Cellular and Molecular Changes in response to selective Il-23 Blockade vs Dual Il-12/23 blockade in Psoriasis Skin presented at the 19th Annual Congress of the European League Against Rheumatism
    • 03 Aug 2017 Results of pooled analysis of 10 trials (NCT00245960, NCT00111449, NCT00663052, NCT00454584) generating evidence concerning the number of patients dropping out of etanercept trials published in the British Journal of Dermatology
    • 08 Mar 2016 Results of an indirect comparison from ACCEPT, UNCOVER 2 and UNCOVER 3 presented at the 74th Annual Meeting of the American Academy of Dermatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top